GLP-1 agonists, widely used to treat type 2 diabetes and manage obesity, were associated with a lower risk of metastatic progression of certain obesity-related cancers, in particular lung, breast, colorectal and liver cancer, according to study results presented at a media briefing in advance of the upcoming American Society of Clinical Oncology Annual Meeting (ASCO 2026)
Change in waist circumference : The mean change in waist circumference was 18.4 cm with tirzepatide (95% CI, 19.6 to 17.2) and 13.0 cm with semaglutide (95% CI, 14.3 to 11.7)
Time to Results: Noticeable Appetite Reduction: GLP-1s (semaglutide, tirzepatide): 1-2 weeks Phentermine: 1-3 days Phentermine-topiramate: 1-2 weeks Naltrexone-bupropion: 4-8 weeks Orlistat: Doesnt reduce appetite Measurable Weight Loss: Tirzepatide: 5-8% by week 20, 15-22% by week 72 Semaglutide: 5-7% by week 20, 10-15% by week 68 Phentermine-topiramate: 5-6% by week 28 Others: 3-5% by week 24-28 GLP-1s produce steady, sustained weight loss over 16-20 months
Absorbs well with a nourishing feel, making it ideal for consistent daily skincare routines
